Clonally selected hypoimmune limbal stem cells: an in vitro proof-of- concept towards an off-the-shelf therapy for limbal stem cell deficiency

The human eye relies on a clear, transparent window called the cornea to focus light and create sharp vision. This window is not a static sheet of glass but a living tissue that constantly renews itself, much like the skin on our arms or legs. This renewal is managed by a small population of specialized cells called limbal stem cells, which reside in a narrow ring at the edge of the cornea. These cells act as a reservoir, dividing to create new corneal cells that migrate inward to replace those worn away by daily use. When this reservoir is damaged or destroyed by injury, infection, or disease, the condition known as limbal stem cell deficiency occurs. Without these cells, the clear cornea is invaded by blood vessels and scar tissue from the surrounding white of the eye, leading to pain, blindness, and the permanent loss of the eye's transparency.

Treating this condition usually involves transplanting healthy stem cells from a donor or from the patient's own healthy eye. However, these procedures face significant hurdles. Using a patient's own eye is often impossible if both eyes are damaged, and using a donor eye carries the risk that the patient's immune system will recognize the new tissue as foreign and attack it, a process called rejection. To prevent this, patients must take powerful drugs to suppress their immune system for the rest of their lives, which carries serious health risks. Furthermore, even with these drugs, many transplants fail because the specific cells used vary from person to person, making it difficult to guarantee a successful outcome. Scientists have long sought a way to create a universal, "off-the-shelf" supply of these cells that could be used for any patient without triggering rejection, but achieving this requires overcoming the body's sophisticated immune defenses.

A team of researchers at Newcastle University has taken a major step toward this goal by engineering a new type of limbal stem cell that can evade the immune system. Their approach involves three specific genetic changes designed to make the cells invisible to the body's defenses while keeping them fully functional. First, they removed the genetic instructions for two specific surface proteins, known as HLA class I and class II, which act like identification badges. Without these badges, the immune system's T-cells cannot recognize the cells as foreign targets to be destroyed. Second, because removing these badges can sometimes trigger a different type of immune attack from natural killer cells, the researchers added a third modification: they increased the production of a protein called CD47. This protein sends a "do not eat" signal to the immune system's cleanup crew, the macrophages, preventing them from swallowing the cells.

To make this engineering possible, the researchers first had to solve a different problem: how to grow these delicate stem cells in a lab for a long time without them dying or losing their special properties. Stem cells are notoriously difficult to keep alive in a dish; they often stop dividing or turn into ordinary skin cells after just a few weeks. The team discovered that adding a specific chemical compound, known as a ROCK inhibitor, to the culture medium allowed the cells to grow continuously. Using this method, they were able to expand the cells for more than 200 generations, a feat that had not been achieved before. Throughout this massive expansion, the cells retained their original identity, looking and behaving exactly like the stem cells found in the human eye, and they remained capable of turning into the different layers of the cornea when needed.

Once they had a stable, healthy supply of these cells, the researchers applied the genetic modifications to create the hypoimmune version. They used a precise gene-editing tool to cut out the genes for the identification badges and inserted a gene to boost the "do not eat" signal. They then grew these modified cells into clones to ensure they were all identical and safe. The results of their testing were striking. When they mixed these engineered cells with human immune cells in a dish, the immune system largely ignored them. The T-cells, which usually multiply rapidly when they encounter foreign tissue, remained quiet and did not attack. Similarly, the macrophages, which usually engulf and destroy foreign cells, left the engineered cells alone. This happened even when the immune cells were stimulated to be highly aggressive, suggesting the cells were effectively invisible to the body's primary defense mechanisms.

Interestingly, the researchers found that the cells' ability to hide from the immune system did not depend on the "do not eat" signal alone. In a surprising discovery, the cells that had only the identification badges removed, but not the extra "do not eat" signal, were also largely ignored by natural killer cells. This suggests that limbal stem cells have some inherent properties that protect them from this specific type of attack, a finding that adds a new layer of understanding to how these cells interact with the immune system. However, the "do not eat" signal was still crucial for preventing the cells from being eaten by macrophages, confirming that the dual strategy of removing identification and adding a protective signal is the most effective approach.

The study also looked at what happens when these cells are allowed to mature into the different layers of the cornea. Even after the cells had differentiated and changed their appearance, they maintained their ability to avoid immune detection. This is a critical finding because a transplant requires not just stem cells, but the ability to form a complete, healthy tissue structure. The researchers confirmed that these engineered cells could still organize themselves into a proper corneal layer and express the correct markers for a healthy eye. They also noted that while the cells were highly effective at avoiding the immune system in the lab, there are still other factors to consider for a real-world treatment, such as blood type compatibility and the potential for the cells to cause other issues if they were to grow uncontrollably.

This work represents a proof-of-concept, meaning it demonstrates that the idea works in a controlled laboratory setting. The researchers have shown that it is possible to create a large, consistent supply of limbal stem cells that are genetically modified to be safe for any patient. While this is not yet a treatment available in a hospital, it lays the groundwork for a future where a patient with blindness in both eyes could receive a transplant without needing to find a matching donor or taking dangerous immune-suppressing drugs. The path from the lab to the clinic will require further testing to ensure long-term safety and effectiveness, but the ability to generate these hypoimmune cells at scale offers a genuine hope for a universal solution to a condition that currently leaves many without a cure.